Literature DB >> 31763765

Rift Valley Fever Virus: Propagation, Quantification, and Storage.

MaRyka R Smith1, Erin E Schirtzinger2, William C Wilson2, A Sally Davis1.   

Abstract

Rift Valley fever virus (RVFV) is an arthropod-borne, zoonotic disease endemic to sub-Saharan Africa and the Arabian Peninsula. Outbreaks of Rift Valley fever have had up to 100% mortality rates in fetal and neonatal sheep. Upon infection of ruminant and human hosts alike, RVFV infection causes an at times severe hepatitis and pathology in many other organs. The enveloped virion contains a tripartite, predominantly negative-sense, single-stranded RNA genome, which codes for the proteins the virus needs to replicate both in mammalian hosts and insect vectors. Endemic countries often use attenuated RVFV strains for vaccination of livestock but there are no commercially licensed vaccines for humans or livestock in non-endemic areas. In the laboratory, RVFV can be readily propagated and manipulated in vitro using cell culture systems. Presented in this article are techniques routinely used in RVFV research that have proven successful in our laboratories.
© 2019 by John Wiley & Sons, Inc. Basic Protocol 1: Propagation of Rift Valley fever virus in mammalian cells Basic Protocol 2: Quantification of Rift Valley fever virus by plaque assay Basic Protocol 3: Quantification of Rift Valley fever virus by 50% tissue culture infectious dose (TCID50 ) assay Basic Protocol 4: Quantification of Rift Valley fever virus by focus-forming assay Basic Protocol 5: Storage and disinfection Alternate Protocol 1: Propagation of Rift Valley fever virus in MRC-5 cells Alternate Protocol 2: Propagation of RVFV in mosquito-derived cells Alternate Protocol 3: TCID50 detection using fluorescence visualization Support Protocol 1: Calculation of the amount of virus needed to infect a flask at a chosen multiplicity of infection Support Protocol 2: Calculation of the virus titer by plaque assay or focus-forming assay Support Protocol 3: Calculation of the TCID50 titer by the method of Reed and Muench Support Protocol 4: Calculation of the antibody volume for the focus-forming assay. © 2019 John Wiley & Sons, Inc.

Entities:  

Keywords:  Rift Valley fever virus; TCID50; bunyaviruses; focus-forming assay; plaque assay; propagation; virology; virus quantification

Mesh:

Year:  2019        PMID: 31763765     DOI: 10.1002/cpmc.92

Source DB:  PubMed          Journal:  Curr Protoc Microbiol        ISSN: 1934-8525


  9 in total

1.  Isolation and Identification of a Novel Phlebovirus, Hedi Virus, from Sandflies Collected in China.

Authors:  Ziqian Xu; Na Fan; Xin Hou; Jing Wang; Shihong Fu; Jingdong Song; Mang Shi; Guodong Liang
Journal:  Viruses       Date:  2021-04-27       Impact factor: 5.048

2.  Characterization of Two Neutralizing Antibodies against Rift Valley Fever Virus Gn Protein.

Authors:  Meng Hao; Guanying Zhang; Shengnan Zhang; Zhengshan Chen; Xiangyang Chi; Yunzhu Dong; Pengfei Fan; Yujiao Liu; Yi Chen; Xiaohong Song; Shuling Liu; Changming Yu; Jianmin Li; Xianzhu Xia
Journal:  Viruses       Date:  2020-02-27       Impact factor: 5.048

3.  An Optimized High-Throughput Immuno-Plaque Assay for SARS-CoV-2.

Authors:  Alberto A Amarilla; Naphak Modhiran; Yin Xiang Setoh; Nias Y G Peng; Julian D J Sng; Benjamin Liang; Christopher L D McMillan; Morgan E Freney; Stacey T M Cheung; Keith J Chappell; Alexander A Khromykh; Paul R Young; Daniel Watterson
Journal:  Front Microbiol       Date:  2021-02-12       Impact factor: 5.640

4.  Tra2beta-Dependent Regulation of RIO Kinase 3 Splicing During Rift Valley Fever Virus Infection Underscores the Links Between Alternative Splicing and Innate Antiviral Immunity.

Authors:  Luke Adam White; Thomas C Bisom; Hunter L Grimes; Miyuki Hayashi; Jean-Marc Lanchy; J Stephen Lodmell
Journal:  Front Cell Infect Microbiol       Date:  2022-01-19       Impact factor: 5.293

Review 5.  Identification and distribution of pathogens coinfecting with Brucella spp., Coxiella burnetii and Rift Valley fever virus in humans, livestock and wildlife.

Authors:  Earl A Middlebrook; Alicia T Romero; Bernard Bett; Daniel Nthiwa; Samuel O Oyola; Jeanne M Fair; Andrew W Bartlow
Journal:  Zoonoses Public Health       Date:  2022-01-15       Impact factor: 2.954

6.  Metal coordinating inhibitors of Rift Valley fever virus replication.

Authors:  Elizabeth Geerling; Valerie Murphy; Maria C Mai; E Taylor Stone; Andreu Gazquez Casals; Mariah Hassert; Austin T O'Dea; Feng Cao; Maureen J Donlin; Mohamed Elagawany; Bahaa Elgendy; Vasiliki Pardali; Erofili Giannakopoulou; Grigoris Zoidis; Daniel V Schiavone; Alex J Berkowitz; Nana B Agyemang; Ryan P Murelli; John E Tavis; Amelia K Pinto; James D Brien
Journal:  PLoS One       Date:  2022-09-16       Impact factor: 3.752

7.  Synthesis and Antiviral Properties against SARS-CoV-2 of Epoxybenzooxocino[4,3-b]Pyridine Derivatives.

Authors:  Alena L Stalinskaya; Nadezhda V Martynenko; Zarina T Shulgau; Alexandr V Shustov; Viktoriya V Keyer; Ivan V Kulakov
Journal:  Molecules       Date:  2022-06-09       Impact factor: 4.927

8.  RIOK3 and Its Alternatively Spliced Isoform Have Disparate Roles in the Innate Immune Response to Rift Valley Fever Virus (MP12) Infection.

Authors:  Thomas C Bisom; Luke A White; Jean-Marc Lanchy; J Stephen Lodmell
Journal:  Viruses       Date:  2022-09-17       Impact factor: 5.818

9.  Correlating qRT-PCR, dPCR and Viral Titration for the Identification and Quantification of SARS-CoV-2: A New Approach for Infection Management.

Authors:  Martina Brandolini; Francesca Taddei; Maria Michela Marino; Laura Grumiro; Agata Scalcione; Maria Elena Turba; Fabio Gentilini; Michela Fantini; Silvia Zannoli; Giorgio Dirani; Vittorio Sambri
Journal:  Viruses       Date:  2021-05-28       Impact factor: 5.048

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.